1 Min Read
Dec 18 (Reuters) - La Jolla Pharmaceutical Co:
* INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC-401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.